The Rule on ‘The Cheaper Medicines Act’ (RA 9502)

🔎 Search our Comprehensive Legal Repository...

SUBJECT: The Rule on ‘The Cheaper Medicines Act’ (RA 9502)

I. Introduction

This memorandum provides an exhaustive analysis of Republic Act No. 9502, otherwise known as the “Universally Accessible Cheaper and Quality Medicines Act of 2008.” The primary legislative intent of the law is to ensure the availability of affordable, quality medicines to all Filipinos by enhancing market competition and regulating the pharmaceutical sector. This research will detail the law’s key provisions, regulatory framework, enforcement mechanisms, and its interplay with other relevant statutes, including intellectual property laws.

II. Statement of Facts

The enactment of RA 9502 was precipitated by the high cost of pharmaceutical products in the Philippines relative to other ASEAN countries. Studies indicated that patent protection, trademark practices, and market structures contributed to inflated prices, placing essential medicines beyond the reach of a significant portion of the population. The law operates on the premise that interventions in patent law, price regulation, and parallel importation are necessary to promote public health and fulfill the state’s constitutional duty to protect the right to health.

III. Statement of the Issue

The central legal issue is: What are the legal frameworks and administrative mechanisms established under RA 9502 to achieve the policy objective of making essential medicines more affordable and accessible to the public, and how do these provisions interact with or modify existing intellectual property regimes under Philippine law?

IV. Applicable Laws and Jurisprudence

Republic Act No. 9502 (The Universally Accessible Cheaper and Quality Medicines Act of 2008).

Republic Act No. 8293 (The Intellectual Property Code of the Philippines).

Republic Act No. 6675 (The Generics Act of 1988).

Republic Act No. 9711 (The Food and Drug Administration Act of 2009).

Executive Order No. 49, s. 1993 (on Government Use of Patents).

Department of Health Administrative Orders and Food and Drug Administration Circulars implementing RA 9502.

World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).

Paris Convention for the Protection of Industrial Property.

Relevant jurisprudence from the Supreme Court on patents, public health, and police power.

V. Discussion of the Law

A. Amendments to the Intellectual Property Code (RA 8293)
RA 9502 introduced critical amendments to the Intellectual Property Code to incorporate flexibilities under the TRIPS Agreement. Key amendments include:

Parallel Importation: Section 72.1 allows for the importation of a patented product which has been sold or placed on the market in any country by the patent owner or with their consent. This promotes international exhaustion of patent rights, enabling the importation of cheaper, legally sourced versions of medicines.

Early Working (Bolar Provision): Section 72.2 permits any person to perform any act necessary to develop and submit information for regulatory approval of a generic drug prior to the expiration of the patent. This facilitates the immediate market entry of generic medicines upon patent expiry.

Government Use: Section 74.1 is strengthened, allowing the government or any authorized third party to exploit a patented invention without the patentee’s authorization for reasons of national security, public health, or public interest. The patentee is entitled to adequate remuneration.

Compulsory Licensing: Sections 93-95 are amended to streamline the process for granting a compulsory license. Grounds include but are not limited to: (a) public interest, particularly national emergencies; (b) anti-competitive practices; and (c) to enable domestic production for export under the Paragraph 6 System of the Doha Declaration for countries with insufficient manufacturing capacity.

B. Price Regulation and Monitoring
The law mandates the President of the Philippines, through the Department of Health (DOH), to regulate the prices of essential medicines. The DOH, in consultation with the Department of Trade and Industry, establishes a Maximum Drug Retail Price (MDRP) and a Maximum Drug Wholesale Price (MDWP) for specific molecules listed in the Philippine National Drug Formulary. Price regulation is considered an exercise of the state’s police power to protect public health.

C. Promotion of Generic Medicines
RA 9502 reinforces RA 6675 (The Generics Act) by mandating the use of generic terminology in all advertisements and promotions, requiring generic labeling, and promoting generic prescribing and dispensing by healthcare professionals. It also encourages the use of International Nonproprietary Names (INN).

D. Transparency in Pharmaceutical Marketing
The law requires full disclosure of benefits, side effects, and costs of medicines to healthcare professionals and consumers. It also mandates the Food and Drug Administration to publish a Philippine National Drug Formulary and a Philippine Essential Drugs List.

E. Strengthening the Food and Drug Administration
The law provided for the institutional strengthening of the FDA (later reinforced by RA 9711) to ensure robust regulation of drug safety, efficacy, and quality, which is a prerequisite for public confidence in lower-cost medicines.

VI. Legal Analysis

The constitutionality of RA 9502 is anchored on the state’s police power and its duty to protect the right to health. The amendments to the Intellectual Property Code represent a careful balancing act between the private rights of patent holders and the public interest in accessing affordable medicines. The provisions on parallel importation, government use, and compulsory licensing are explicit implementations of TRIPS flexibilities, which are permissible under international treaty obligations. The price regulation mechanism, while potentially impacting property rights and freedom of enterprise, is justified as a reasonable and necessary measure to address a pressing public health concern. The law’s success hinges on the effective implementation by the DOH, FDA, and the Intellectual Property Office.

VII. Comparative Analysis of Key TRIPS Flexibilities

The following table compares the key TRIPS flexibilities as implemented under the pre-9502 Intellectual Property Code and under RA 9502.

TRIPS Flexibility	Pre-RA 9502 (RA 8293) Framework	Post-RA 9502 (Amended RA 8293) Framework
Parallel Importation	Ambiguous; doctrine of international exhaustion not explicitly stated.	Explicitly adopted. Section 72.1 allows importation of a product sold anywhere by the patentee or with consent.
Early Working (Bolar Provision)	Not explicitly provided, creating legal risk for generic companies.	Explicitly allowed under Section 72.2 for purposes of regulatory approval.
Government Use	Provided under Section 74 but with less detailed procedures and scope.	Strengthened; clarifies scope for public health and national emergencies; procedures for remuneration detailed.
Compulsory Licensing	Procedures were complex and grounds were less specific to public health.	Streamlined process; grounds expanded to explicitly include public health, national emergencies, and anti-competitive practices.
Patentability Criteria	Standard criteria (novelty, inventive step, industrial applicability) applied.	Introduced Section 22.1: The mere discovery of a new form or new use of a known substance does not result in inventive step unless it yields a surprising result, preventing evergreening.

VIII. Recommendations

For the Department of Health: Proactively review and expand the list of medicines under the MDRP/MDWP scheme based on current public health needs and market studies.

For the Intellectual Property Office: Develop clear and expedited administrative procedures for compulsory license applications to ensure the mechanism is a viable tool in health crises.

For the Food and Drug Administration: Accelerate the registration process for generic medicines and biosimilar products to increase market competition.

For Legislators: Consider amendments to further strengthen penalties for violations of the law’s transparency and pricing provisions.

For Healthcare Institutions: Strictly implement the Generics Act provisions reinforced by RA 9502, including mandatory generic prescribing where applicable.

IX. Potential Challenges and Limitations

Legal Challenges: Patent holders may contest compulsory licenses or price regulation orders, leading to protracted litigation.

Administrative Capacity: Effective implementation requires significant regulatory capacity from the DOH, FDA, and IPO, which may be hampered by resource constraints.

Market Dynamics: The law cannot fully control supply chain mark-ups or ensure the economic viability of local generic manufacturers.

Global Agreements: Future free trade agreements containing TRIPS-plus provisions (e.g., extended data exclusivity) could undermine the flexibilities utilized by RA 9502.

X. Conclusion

Republic Act No. 9502 is a comprehensive legislative measure that employs multiple legal and regulatory strategies to lower drug prices. By amending the Intellectual Property Code to incorporate TRIPS flexibilities, instituting a framework for price regulation, and reinforcing policies for generic medicine promotion, the law provides a multifaceted approach to a complex public health issue. Its ultimate efficacy remains dependent on vigilant and capable implementation by concerned government agencies and sustained political will to prioritize public health over purely commercial interests.

Hot topics

Rhetoric Digests

SC Decisions

Legal Research

Case Digests